Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
Expanding clinical trial eligibility criteria: Risks and solutions

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.06.19
Views: 592

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Dr Jorge Nieva speaks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about a study which demonstrated the need to amend eligibility criteria for patients with advanced NSCLC in clinical trials.

He emphasises that these inclusion and exclusion criteria must change, as many patients are excluded from participating in clinical trials.

Dr Nieva also discusses the risks associated with expanding clinical trial criteria, which include allowing more patients with renal dysfunction, brain metastases and other significant co-morbidities to participate in these trials. To counteract this, he mentions some methods that can objectively stratify this larger patient population.

He concludes by describing a current clinical trial which uses digital tools to objectively quantify performance status in early-stage clinical trials.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation